| |
Baseline to Phase 2 (2.6 year follow up)
|
Baseline to Phase 3 (5 year follow up)
|
|---|
| |
Step 1: Multivariable β
|
Step 2: Multivariable β
|
Step 1: Multivariable β
|
Step 2: Multivariable β
|
|---|
| |
(adj. age sex BMI, change in BMI and age over time)
|
Adjusted further¥
|
(adj. age sex BMI, change in BMI and age over time)
|
Adjusted furtherϒ
|
|---|
|
Diagnosed OA of:
| | | | |
|
Neck
|
1.55 (0.96 to 2.15)
|
0.01 (−0.5 to 0.52)
| | |
|
Shoulders
|
1.92 (1.22 to 2.61)
|
0.37 (−0.23 to 0.96)
| | |
|
Back
|
1.76 (1.23 to 2.28)
|
0.59 (0.12 to 1.06)
| | |
|
Hips
|
1.19 (0.54 to 1.84)
|
−0.20 (−0.73 to 0.32)
| | |
|
Hands
|
1.35 (0.79 to 1.90)
|
0.19 (−0.28 to 0.66)
| | |
|
Knees
|
1.50 (0.91 to 2.08)
|
0.15 (−0.34 to 0.64)
| | |
|
Feet
|
1.40 (0.72 to 2.09)
|
0.12 (−0.44 to 0.68)
| | |
|
Presence or absence of pain in the:
| | | |
|
Neck
|
1.79 (1.4 to 2.18)
|
0.55 (0.19 to 0.91)
|
1.20 (0.89 to 1.51)
|
0.42 (0.14 to 0.71)
|
|
Shoulders
|
1.80 (1.42 to 2.18)
|
0.66 (0.31 to 1.00)
|
1.36 (1.06 to 1.66)
|
0.64 (0.36 to 0.91)
|
|
Back
|
1.82 (1.45 to 2.19)
|
0.67 (0.33 to 1.00)
|
1.39 (1.09 to 1.68)
|
0.66 (0.39 to 0.94)
|
|
Hips
|
1.46 (1.07 to 1.85)
|
0.52 (0.19 to 0.85)
|
1.16 (0.85 to 1.47)
|
0.47 (0.20 to 0.74)
|
|
Hands
|
1.20 (0.82 to 1.59)
|
0.19 (−0.13 to 0.51)
|
0.91 (0.60 to 1.22)
|
0.27 (0.01 to 0.53)
|
|
Knees
|
1.51 (1.12 to 1.90)
|
0.43 (0.10 to 0.75)
|
1.10 (0.79 to 1.41)
|
0.44 (0.17 to 0.70)
|
|
Feet
|
0.98 (0.65 to 1.32)
|
0.36 (0.09 to 0.62)
|
0.75 (0.47 to 1.02)
|
0.26 (0.03 to 0.49)
|
- Statistically significant (p ≤ 0.05) results indicated in bold type.
-
¥ Results further adjusted for diagnosed OA at all sites, pain at all sites, presence of rheumatoid arthritis and leg strength.
-
ϒResults further adjusted as for the analyses for Baseline to Phase 2, but without Diagnosed OA as this was not asked at Phase 3.
- 5 year follow up data includes data collected at Phase 1, 2 and 3 and is not limited to participants with complete data.
- Radiographs not included as they were only collected at Phase 1.
